Fluorinov Pharma (Trillium)

facit.ca
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
Breakthrough medicinal chemistry technology enabling fluorine atoms linked to drug candidates to improve therapeutic potency, stability and safety. The lead candidate, FV162, is an oral proteasome inhibitor for the treatment of blood cancers.

Related news

Trillium Therapeutics Acquires Fluorinov Pharma

Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company. Read More

Fluorinov Pharma Inc. develops drug for the treatment of blood cancers

OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma. Read More

Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers

TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets. Read More

Fluorinov, FACIT and OICR announce novel candidate drugs

The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.